|

Testosterone Cypionate Clinical Trials

6 actively recruiting trials across 4 locations

▼ -1 trial since August 2026

Also known as: DEPO-Testosterone, DEPO-Testosterone Injection, Depo-Testosterone, Depo-Testosterone Injection, Depotest +4 more

Pipeline

Phase 2: 6

Top Sponsors

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4
  • Yale University1
  • University of Washington1

Indications

  • Cancer6
  • Metastatic Castration-resistant Prostate Cancer3
  • Castration Resistant Metastatic Prostate Cancer1
  • Castration-Resistant Prostate Carcinoma1
  • Stage IVB Prostate Cancer AJCC v81

Baltimore, Maryland3 trials

Difluoromethylornithine and High Dose Testosterone With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer

Johns Hopkins University: Sidney Kimmel Comprehensive Cancer Center

Phase 2
Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2
The COSMYC Trial (COmbined Suppression of MYC)

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Phase 2

San Diego, California1 trial

Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression

University of California, San Diego (UCSD)

Phase 2

New Haven, Connecticut1 trial

Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC

Yale Cancer Center

Phase 2

Seattle, Washington1 trial

Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.